ValuEngine upgraded shares of Alder BioPharmaceuticals (NASDAQ:ALDR) from a strong sell rating to a sell rating in a research report sent to investors on Thursday, January 4th.
Other research analysts have also issued research reports about the company. BMO Capital Markets reissued a buy rating and set a $22.00 price target on shares of Alder BioPharmaceuticals in a research note on Wednesday, January 3rd. BidaskClub raised Alder BioPharmaceuticals from a sell rating to a hold rating in a research note on Thursday, January 4th. Royal Bank of Canada began coverage on Alder BioPharmaceuticals in a research note on Thursday, September 14th. They set an outperform rating and a $17.00 price target on the stock. Canaccord Genuity began coverage on Alder BioPharmaceuticals in a report on Thursday, October 26th. They set a buy rating and a $20.00 price objective for the company. Finally, Mizuho restated a buy rating and set a $32.00 price objective on shares of Alder BioPharmaceuticals in a report on Wednesday, November 8th. Three research analysts have rated the stock with a sell rating, two have issued a hold rating and eleven have issued a buy rating to the stock. Alder BioPharmaceuticals presently has an average rating of Buy and a consensus target price of $27.93.
Alder BioPharmaceuticals (NASDAQ ALDR) traded down $0.05 during mid-day trading on Thursday, reaching $17.85. The company had a trading volume of 1,437,000 shares, compared to its average volume of 2,473,333. Alder BioPharmaceuticals has a 12-month low of $8.60 and a 12-month high of $25.45. The stock has a market cap of $1,211.00, a price-to-earnings ratio of -3.33 and a beta of 2.48.
In related news, insider Mark James Litton sold 16,519 shares of the stock in a transaction on Monday, November 13th. The stock was sold at an average price of $10.80, for a total value of $178,405.20. Following the completion of the sale, the insider now directly owns 116,451 shares in the company, valued at approximately $1,257,670.80. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 10.60% of the stock is currently owned by corporate insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in ALDR. Quantitative Systematic Strategies LLC acquired a new stake in Alder BioPharmaceuticals in the 3rd quarter valued at $132,000. Legal & General Group Plc grew its stake in shares of Alder BioPharmaceuticals by 2.6% during the second quarter. Legal & General Group Plc now owns 15,496 shares of the biopharmaceutical company’s stock valued at $177,000 after acquiring an additional 400 shares in the last quarter. SG Americas Securities LLC grew its stake in shares of Alder BioPharmaceuticals by 109.4% during the second quarter. SG Americas Securities LLC now owns 15,580 shares of the biopharmaceutical company’s stock valued at $178,000 after acquiring an additional 8,140 shares in the last quarter. Jane Street Group LLC acquired a new stake in shares of Alder BioPharmaceuticals during the third quarter valued at about $184,000. Finally, Voya Investment Management LLC grew its stake in shares of Alder BioPharmaceuticals by 8.4% during the second quarter. Voya Investment Management LLC now owns 22,304 shares of the biopharmaceutical company’s stock valued at $255,000 after acquiring an additional 1,734 shares in the last quarter. Hedge funds and other institutional investors own 96.80% of the company’s stock.
WARNING: “Alder BioPharmaceuticals (ALDR) Rating Increased to Sell at ValuEngine” was originally reported by BBNS and is the sole property of of BBNS. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international copyright law. The legal version of this report can be viewed at https://baseballnewssource.com/markets/alder-biopharmaceuticals-aldr-raised-to-sell-at-valuengine/1818194.html.
About Alder BioPharmaceuticals
Alder BioPharmaceuticals, Inc, is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Alder BioPharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder BioPharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.